| pubmed-article:11787527 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11787527 | lifeskim:mentions | umls-concept:C1522449 | lld:lifeskim |
| pubmed-article:11787527 | lifeskim:mentions | umls-concept:C0333678 | lld:lifeskim |
| pubmed-article:11787527 | lifeskim:mentions | umls-concept:C0040113 | lld:lifeskim |
| pubmed-article:11787527 | lifeskim:mentions | umls-concept:C0229601 | lld:lifeskim |
| pubmed-article:11787527 | lifeskim:mentions | umls-concept:C0003241 | lld:lifeskim |
| pubmed-article:11787527 | lifeskim:mentions | umls-concept:C0010583 | lld:lifeskim |
| pubmed-article:11787527 | lifeskim:mentions | umls-concept:C0009647 | lld:lifeskim |
| pubmed-article:11787527 | lifeskim:mentions | umls-concept:C1704410 | lld:lifeskim |
| pubmed-article:11787527 | lifeskim:mentions | umls-concept:C0205360 | lld:lifeskim |
| pubmed-article:11787527 | lifeskim:mentions | umls-concept:C1533691 | lld:lifeskim |
| pubmed-article:11787527 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:11787527 | lifeskim:mentions | umls-concept:C0181586 | lld:lifeskim |
| pubmed-article:11787527 | lifeskim:mentions | umls-concept:C0205430 | lld:lifeskim |
| pubmed-article:11787527 | lifeskim:mentions | umls-concept:C1515655 | lld:lifeskim |
| pubmed-article:11787527 | lifeskim:mentions | umls-concept:C0443252 | lld:lifeskim |
| pubmed-article:11787527 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:11787527 | pubmed:dateCreated | 2002-1-11 | lld:pubmed |
| pubmed-article:11787527 | pubmed:abstractText | Successful transplantation of solid organs relies on long-term immunosuppression for the prevention of graft rejection. Donor-specific tolerance without the need for continuous immunosuppression can be observed after allogeneic BMT. However, its routine use for tolerance induction has been precluded so far by the high conditioning-related toxicity of standard BMT regimens. Our laboratory has recently established a cyclophosphamide (CTX) plus thymic irradiation (TI)-based nonmyeloablative conditioning protocol for the treatment of hematologic malignancies. We have recently described the successful clinical application of this approach for the induction of donor-specific tolerance in a patient receiving a living-related kidney transplant, which resulted in graft acceptance without long-term immunosuppression. The aim of this study was to evaluate the induction and maintenance of host-versus-graft tolerance following this CTX-plus-TI-based regimen in a mouse model. | lld:pubmed |
| pubmed-article:11787527 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11787527 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11787527 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11787527 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11787527 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11787527 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11787527 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11787527 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11787527 | pubmed:issn | 1083-8791 | lld:pubmed |
| pubmed-article:11787527 | pubmed:author | pubmed-author:PearsonDD | lld:pubmed |
| pubmed-article:11787527 | pubmed:author | pubmed-author:SykesMM | lld:pubmed |
| pubmed-article:11787527 | pubmed:author | pubmed-author:ZhaiMM | lld:pubmed |
| pubmed-article:11787527 | pubmed:author | pubmed-author:SwensonKK | lld:pubmed |
| pubmed-article:11787527 | pubmed:author | pubmed-author:MaparaM YMY | lld:pubmed |
| pubmed-article:11787527 | pubmed:author | pubmed-author:PelotMM | lld:pubmed |
| pubmed-article:11787527 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11787527 | pubmed:volume | 7 | lld:pubmed |
| pubmed-article:11787527 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11787527 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11787527 | pubmed:pagination | 646-55 | lld:pubmed |
| pubmed-article:11787527 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:11787527 | pubmed:meshHeading | pubmed-meshheading:11787527... | lld:pubmed |
| pubmed-article:11787527 | pubmed:meshHeading | pubmed-meshheading:11787527... | lld:pubmed |
| pubmed-article:11787527 | pubmed:meshHeading | pubmed-meshheading:11787527... | lld:pubmed |
| pubmed-article:11787527 | pubmed:meshHeading | pubmed-meshheading:11787527... | lld:pubmed |
| pubmed-article:11787527 | pubmed:meshHeading | pubmed-meshheading:11787527... | lld:pubmed |
| pubmed-article:11787527 | pubmed:meshHeading | pubmed-meshheading:11787527... | lld:pubmed |
| pubmed-article:11787527 | pubmed:meshHeading | pubmed-meshheading:11787527... | lld:pubmed |
| pubmed-article:11787527 | pubmed:meshHeading | pubmed-meshheading:11787527... | lld:pubmed |
| pubmed-article:11787527 | pubmed:meshHeading | pubmed-meshheading:11787527... | lld:pubmed |
| pubmed-article:11787527 | pubmed:meshHeading | pubmed-meshheading:11787527... | lld:pubmed |
| pubmed-article:11787527 | pubmed:meshHeading | pubmed-meshheading:11787527... | lld:pubmed |
| pubmed-article:11787527 | pubmed:meshHeading | pubmed-meshheading:11787527... | lld:pubmed |
| pubmed-article:11787527 | pubmed:meshHeading | pubmed-meshheading:11787527... | lld:pubmed |
| pubmed-article:11787527 | pubmed:meshHeading | pubmed-meshheading:11787527... | lld:pubmed |
| pubmed-article:11787527 | pubmed:meshHeading | pubmed-meshheading:11787527... | lld:pubmed |
| pubmed-article:11787527 | pubmed:meshHeading | pubmed-meshheading:11787527... | lld:pubmed |
| pubmed-article:11787527 | pubmed:meshHeading | pubmed-meshheading:11787527... | lld:pubmed |
| pubmed-article:11787527 | pubmed:meshHeading | pubmed-meshheading:11787527... | lld:pubmed |
| pubmed-article:11787527 | pubmed:meshHeading | pubmed-meshheading:11787527... | lld:pubmed |
| pubmed-article:11787527 | pubmed:meshHeading | pubmed-meshheading:11787527... | lld:pubmed |
| pubmed-article:11787527 | pubmed:meshHeading | pubmed-meshheading:11787527... | lld:pubmed |
| pubmed-article:11787527 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11787527 | pubmed:articleTitle | Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance. | lld:pubmed |
| pubmed-article:11787527 | pubmed:affiliation | Transplantation Biology Research Center, Bone Marrow Transplantation Section, Massachusetts General Hospital, Harvard Medical School, Boston 02129, USA. | lld:pubmed |
| pubmed-article:11787527 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11787527 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:11787527 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:11787527 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11787527 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11787527 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11787527 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11787527 | lld:pubmed |
